Patience David

CFO Patience David buys 7,100 shares of TLSI at $2.43; stock down -34.8% in 30 days as cluster buy emerges.

Patience David, CFO of TriSalus Life Sciences, purchased 7,100 shares at $2.43 on 2026-05-15, increasing holdings to 275,757 shares. The timing is notable: the stock has declined -34.8% over the past 30 days and -36.5% over 90 days, trading at $3.03 (down -61.9% from its 52-week high of $7.95). His prior open-market buy at this ticker on 2026-02-23 resulted in a -34.6% 90-day return, and his cross-ticker track record shows zero wins from one prior buy (avg 90d return -34.6%). The transaction occurs amid a cluster pattern: 3 other insiders also bought within the past 14 days. While the company shows strong fundamentals—annual revenue growth of +53.4%, latest quarterly revenue of $8,899,000.00, and net income of $1,539,000.00—it was unprofitable over its most recent full fiscal year, creating a mixed signal between growth trajectory and profitability.

CFO Patience David bought 3,657 shares of TLSI at $4.10; cluster of 4 other insider buys in past 14 days amid -33.5% 52-week drawdown

Patience David, CFO of TriSalus Life Sciences, purchased 3,657 shares at $4.10 on 2026-02-23, increasing her holdings from 265.0K to 268.7K shares. This transaction is part of a broader cluster: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence despite deteriorating market conditions. The stock trades at $4.99 today, down -33.5% from its 52-week high of $7.50 and down -8.3% over 30 days, indicating the company is in a significant drawdown. While the company posted +59.0% annual revenue growth, it remains deeply unprofitable with a -$10.8M net loss in the latest quarter against $11.6M in quarterly revenue, highlighting a critical profitability gap. The cluster buy pattern during a sharp price decline warrants examination of whether insiders are accumulating at depressed levels or responding to operational headwinds.